Compare Heron Therapeutics Inc (HRTX) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Global X Uranium ETF — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Global X Uranium ETF trades at $38.9 (market cap $5.48B). The key difference: Global X Uranium ETF is far larger — about 80.6× Heron Therapeutics Inc's market cap, and Global X Uranium ETF is more actively traded (5,287,170 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Global X Uranium ETF for 62 Days on average.
| HRTX | URA | |
|---|---|---|
Market Cap | $68.01M | $5.48B |
Volume | 1,891,941 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.49 | $61.81 |
52-Week Low | $0.27 | $37.52 |
Typical Hold Time | 35 Days | 62 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
URA (Global X Uranium ETF) trades at $38.90, down 2.58% with a bearish technical signal. The ETF faces pressure from recent uranium sector volatility despite positive long-term nuclear energy demand drivers. Key support levels cluster around $37-38 while resistance sits at $39-41. Recent news highlights both opportunities from AI power demand growth and risks from sector-specific headwinds.
The uranium sector faces near-term volatility but benefits from structural tailwinds including AI power demand and global nuclear expansion. Investment opportunities exist through diversified uranium exposure, though risks include commodity price sensitivity and regulatory uncertainty. Current technical weakness suggests cautious entry points may emerge near support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
